<http://webisa.webdatacommons.org/67147400>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<sec.gov> .
<http://webisa.webdatacommons.org/prov/351626154>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/67147400> .
<http://webisa.webdatacommons.org/67147400>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/prov/277118563>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/67147400> .
<http://webisa.webdatacommons.org/67147400>	<http://www.w3.org/ns/prov#value>	"ATX-101, if approved, will compete with new and existing therapies for the treatment of localized fat, including, liposuction and other surgical procedures, as well as other new" .